Summary
The AI response correctly identifies Vivitrol as a naltrexone injection and supports monthly administration based on the label. It correctly marks the billing-related claim as absent from the label. It omits other label details related to administration and dosing specifics.
Category Scores
Accurate Statements
Vivitrol is a naltrexone injection.
11 DESCRIPTION; 2.1
Unsupported Statements
Missed-dose timing can change how many doses you’re billed for.
Billing considerations are not addressed in the FDA label.
Contradictions
Important Omissions
Did not state that VIVITROL must be administered by a healthcare provider via deep intramuscular gluteal injection; did not mention needle length considerations and the specific dosing of 380 mg every 4 weeks.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
No new safety risks identified; evaluation focuses on label alignment.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement